PUTNAM, CT – (April 2, 2013) - Foster Corporation, a leader in custom polymer compounds for medical devices, now offers nano-reinforced composites for minimally invasive devices, such as catheters, with reinforcement loadings up to 30% by weight. Nano-reinforced compounds with high filler loadings provide substantial increase in physical properties of the base resin while maintaining processibility in thin wall components.
PUTNAM, CT – (December 13, 2012) – Foster Corporation, a leader in custom polymer formulations for medical device and drug delivery applications, now offers regional technical service and product development support in Asia Pacific. Amar Nilajkar, a ten year veteran of the company, will support medical device and pharmaceutical customers in the region from a newly established office in India.
PUTNAM, CT – (November 14, 2012) – Foster Corporation today announced it ranked in Deloitte’s Technology Fast 500™, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. Foster Corporation grew 149% percent from 2007 to 2011.
Putnam, CT, USA -- (October 16, 2012) -- Foster Corporation, a leader in custom medical polymers, reports increased interest in implantable medical device applications by polymer suppliers. While risk mitigation remains a primary concern, increased acceptance and application of polymers by device manufacturers for temporary and permanent implants presents opportunities for growth for performance polymers.
Putnam, CT, USA -- (August 6, 2012) -- Foster Corporation, a leader in custom medical polymers, has been recognized as one of Connecticut's 40 fastest growing technology companies in 2012 by the Connecticut Technology Council (CTC) and Marcum LLP. This marks the 9th time in the past 15 years that Foster has been recognized as one of the fastest growing technology companies by CTC and Marcum LLP.
PUTNAM, CT, USA – (June 11, 2012) – Foster Delivery Science, a business unit of Foster Corporation that specializes in contract development and manufacturing of implant and drug delivery polymers, now offers custom radiopaque PEEK compounds for use in long term orthopedic implants. A twin screw extruder within the company’s Class 7 cGMP clean room is designed to produce development PEEK compound batches as small at 5 lbs (2.27 kg) through production quantities.
PUTNAM, CT, USA – (May 22, 2012) – Foster Corporation, a leader in custom medical polymers, has added state-of-the-art extrusion compounding capacity for custom pre-colored polymers used in Class I medical applications. The new line is designed to optimize pigment dispersion of challenging colors and polymers, and maximize throughput necessary to reduce compounding costs.
King of Prussia, PA -- Arkema Inc. has implemented a 12-month advance notice for product specification changes on all Pebax® SA 01 MED polymers in order to provide medical device manufacturers with the necessary time for regulatory assessment. Previously, notifications of change for these polymers sold in the medical market were unrestricted, similar to grades sold in non-medical markets.
Foster Analytical Services Speeds Time to Market for Drug Delivery Formulations Using Hot Melt Extrusion
PUTNAM, CT, USA – (January 31, 2012) – Foster Delivery Science, a business unit for Foster Corporation, has added comprehensive in-house laboratory services to expedite the screening of early stage formulations, process development, and post-extrusion studies of solid dose drug delivery forms using hot melt extrusion. As a contract research and manufacturing company that specializes in hot melt extrusion, Foster Delivery Science analytical services includes thermal analysis, spectroscopy,and chromatography equipment specifically designed for solid ora
Putnam, CT, USA – (September 8, 2011) – Foster Corporation, a PolyMedex Discovery Group company and leader in biomedical materials, has introduced custom extruded film and rod from drug/polymer blends for implant, patch and oral drug delivery applications. Working with customer specified active pharmaceutical ingredients and a range of polymer formulations, including EVA, bioresorbable and water soluble polymers, Foster is able to support customers from formulation development through clinical production of advanced drug delivery systems.